Parent Project Muscular Dystrophy
View in browser.
Parent Project Muscular Dystrophy

Nov 20 Webinar: NS Pharma Provides Viltolarsen Update



NS Pharma will join Parent Project Muscular Dystrophy for a webinar Wednesday, November 20 at 1pm eastern to provide the community with an overview of its investigational drug, viltolarsen (NS-065/NCNP-01), including its mechanism of action and regulatory status. NS Pharma will also provide an update on the viltolarsen clinical program, including the completed Phase 1, Phase 1/2, and Phase 2 studies. They will also discuss the viltolarsen Phase 3 trial (RACER53), including anticipated countries where the study will be conducted, study design, description of the endpoints, and inclusion/exclusion criteria.


  • Abby Bronson
    Senior Vice President, Research Strategy
    Parent Project Muscular Dystrophy


  • Angela Melia
    Associate Director, Research & Development
    NS Pharma
  • Paula R. Clemens, MD
    Study Chair, NS-065/NCNP-01-201 study and NS-065/NCNP-01-202 study Medical Director, CINRG
    Professor and Vice Chair, Neurology, University of Pittsburgh School of Medicine
    Division Chief, Neurology Service, VA Pittsburgh Healthcare System

Please submit questions in advance to (subject line: NS Pharma Webinar) by Monday, November 18 at 12pm eastern.


© Parent Project Muscular Dystrophy | Contact Us | Privacy Policy

1-800-714-5437 | | 401 Hackensack Avenue, 9th Floor, Hackensack, NJ 07601

Was this e-mail forwarded to you? Subscribe today.
Unsubscribe from receiving email or change your email preferences.

powered by Blackbaud
nonprofit software